{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hyperthyroidism/background-information/prevalence/","result":{"pageContext":{"chapter":{"id":"a8477f19-2c3c-55eb-9cf0-52683adbf104","slug":"prevalence","fullItemName":"Prevalence","depth":2,"htmlHeader":"<!-- begin field b93b0f08-69ff-4072-8364-560a2b9703cf --><h2>How common is it?</h2><!-- end field b93b0f08-69ff-4072-8364-560a2b9703cf -->","summary":"","htmlStringContent":"<!-- begin item edbddd0c-6a76-4ac6-b07e-6f3b8ffb4375 --><!-- begin field 94ff5d2f-e0fc-4183-a719-51e96be98336 --><h3>Overt and subclinical hyperthyroidism</h3><ul><li>A meta-analysis of 17 European studies of thyroid dysfunction found that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Madariaga et al, 2014</a>]:<ul><li>The total prevalence (diagnosed and undiagnosed) of hyperthyroidism was 0.75%.</li><li>The prevalence of undiagnosed hyperthyroidism was 1.72% (1.71% in females and 1.81% in males); and the prevalence of undiagnosed subclinical hyperthyroidism was 0.42% in females and 0.27% in males.</li><li>The incidence rate of hyperthyroidism was 51.04 per 100,000 people per year; 82.47 per 100,000 women per year and 16.24 per 100,000 men per year.</li></ul></li><li>The prevalence of hyperthyroidism increases with age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>].</li><li>A UK follow-up community survey of thyroid disease found the prevalence of hyperthyroidism in women was 0.5–2%, and it was ten times more common in women than in men [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vanderpump et al, 1995</a>].</li><li>The prevalence of subclinical hyperthyroidism increases with age and is higher in iodine-deficient areas, such as Denmark, compared with iodine-sufficient areas, such as the UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Cooper and Biondi, 2012</a>].<ul><li>In England, the prevalence of subclinical hyperthyroidism was found to be 2.1% in a cross-sectional screening survey of 5,950 adults aged over 65 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Franklyn and Boelaert, 2012</a>].</li></ul></li></ul><h3>Graves' orbitopathy</h3><ul><li>Graves' orbitopathy is an uncommon autoimmune condition with an estimated incidence of 16 women and 3 men per 100,000 population per year [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Daumerie, 2010</a>]. The prevalence of Graves' orbitopathy has decreased in recent years, possibly due to earlier diagnosis and treatment of Graves' disease by endocrinologists and ophthalmologists [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bartalena, 2016</a>].<ul><li>More than 90% of cases occur in people presenting with hyperthyroidism due to Graves' disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Perros et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>], but it may also present up to a year before the onset of hyperthyroidism, or up to 5 years after a diagnosis of hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Lazarus, 2012</a>].</li><li>It is seen in 40% of people with Graves' disease who have <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/diagnosis/\">eyelid signs</a>. Severe Graves' orbitopathy is diagnosed in 3–5% of these cases, and is more common in older people and men [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Daumerie, 2010</a>].</li></ul></li><li>A large prospective Danish population-based study which analyzed approximately 8.9 million person-years of observational data, found the incidence of new cases of moderate-to-severe Graves' orbitopathy was 0.161 per 10,000 people per year [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Laurberg, 2012</a>].</li><li>The European Group on Graves’ Orbitopathy (EUGOGO) position statement states that cross-sectional studies from secondary or tertiary centres have found 2% of cases of Graves' orbitopathy were sight-threatening [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Perros, 2017</a>].</li></ul><h3>Pregnancy and postpartum</h3><ul><li>The risk of developing hyperthyroidism in pregnancy varies depending on the stage of pregnancy. A Danish population-based cohort study (n = 403,958) reported that overall, 0.9% of women developed hyperthyroidism in and around the time of pregnancy, with an incidence rate of 65 per 100,000 women per year. It found [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Andersen, 2015</a>]:<ul><li>A high incidence rate during the first trimester (relative risk [RR 1.5]).</li><li>A low incidence rate during the third trimester (RR 0.26).</li><li>The highest incidence rate was in the 7–9 months postpartum (RR 3.8).</li></ul></li><li>The Endocrine Society clinical practice guideline notes that the prevalence of hyperthyroidism in pregnancy is 0.1–0.4%, and Graves' disease accounts for 85% of these cases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>].<ul><li>The American Thyroid Association (ATA) guideline notes that hyperthyroidism due to Graves' disease occurs in 0.5–1.0% of women in the reproductive age range, and 0.1–0.2% of these women are treated with antithyroid drugs during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>].</li></ul></li><li>The mean prevalence of postpartum thyroiditis in prospective studies in iodine-sufficient areas is about 7% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>].</li></ul><!-- end field 94ff5d2f-e0fc-4183-a719-51e96be98336 --><!-- end item edbddd0c-6a76-4ac6-b07e-6f3b8ffb4375 -->","topic":{"id":"c3c8bd52-950a-5ac1-a8f6-31ee314de753","topicId":"4369594d-9952-48d2-89e3-17e591c8762d","topicName":"Hyperthyroidism","slug":"hyperthyroidism","lastRevised":"Last revised in January 2021","chapters":[{"id":"59f9bdf8-6311-583d-9fe9-52c678d352db","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"146e5bec-d1eb-5ba0-9e81-f3816c76c97a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"129b45b2-8296-54fd-9b82-246f53a0c38a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"94bb9adc-590a-5092-a39d-eafdcb359b5b","slug":"changes","fullItemName":"Changes"},{"id":"0587f71f-c66c-57d3-82dc-d217875883ba","slug":"update","fullItemName":"Update"}]},{"id":"1056d2a8-5a53-5386-8dab-1f19fc4a963f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d5707303-4d8e-53dd-9591-510f1f75ea88","slug":"goals","fullItemName":"Goals"},{"id":"c725a50c-0e88-5dca-a743-83b0aec2cf6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"423f188d-b3d1-599b-b36e-d8986253ac12","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a7f71a23-ba29-5115-a37a-e10730ecfebe","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3769fad6-d54a-5b84-9378-d5fed321c43f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f546d633-22ad-5b3a-addf-c14ed5a316e4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a47d1c6f-bb45-556c-9f6f-1be5eb0fee97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"87205244-f824-5403-8c75-27a9396c3d3c","slug":"definition","fullItemName":"Definition"},{"id":"297effea-8b73-56d9-b953-894efa713b64","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6c2d617f-c4bf-53cd-ad15-3c4e50b4f917","slug":"causes","fullItemName":"Causes"},{"id":"a8477f19-2c3c-55eb-9cf0-52683adbf104","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5d8a6eb0-ae1c-5dc0-976b-c6dc76c822d0","slug":"complications","fullItemName":"Complications"},{"id":"606c2ced-041a-59db-84ad-9bdbc9d30b29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"25bebca1-01a3-571a-bc2f-de52655661fd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"535b7a8d-3411-51df-831d-85332e2925e0","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3e2f3be8-a4e7-55cc-a90e-fc9bc179ce65","slug":"assessment","fullItemName":"Assessment"}]},{"id":"c4bec08d-e5b3-509c-bea9-a31e8270f443","fullItemName":"Management","slug":"management","subChapters":[{"id":"4b553103-7c9a-5df2-a66d-ca71eb230d75","slug":"management","fullItemName":"Scenario: Management"},{"id":"f01fb4b1-5479-506a-aab6-3d89022ca8d1","slug":"pre-conception-pregnancy-postpartum","fullItemName":"Scenario: Pre-conception, pregnancy, and postpartum"}]},{"id":"410c1a25-4e25-5a82-9e68-74da126c2a52","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8a4baacf-8743-54dd-b0d2-6f9c63faed0f","slug":"propylthiouracil","fullItemName":"Propylthiouracil"},{"id":"5fecf90d-1aa4-5bb3-9e03-3603d3bff170","slug":"carbimazole","fullItemName":"Carbimazole"},{"id":"9f0433e8-fb86-5755-b708-070c08e61a4e","slug":"beta-blockers","fullItemName":"Beta-blockers"}]},{"id":"d5890c99-4277-5691-82b8-db4d899a0577","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02257fcd-f37e-5344-be29-947639722e86","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ad43c9e6-b7b5-5112-a0c3-cceb0846f218","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19745d5f-1ede-5a4c-bc7f-14ffd9dcb077","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"28c4e1a4-4c14-58af-a7eb-7064465157f4","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"afef01bd-ae56-54fa-96f9-395242020ab0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1fc2600e-afe1-582b-b40e-ba61a21de9f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b29c805a-fe2a-529d-a4e8-e0a837f7663c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a47d1c6f-bb45-556c-9f6f-1be5eb0fee97","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}